Transition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency
Tweet Send to a Friend
Transition Therapeutics Inc. (Nasdaq: TTHI) announced the dosing of the first patient of a Phase 2 study of selective androgen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
